Day: August 13, 2024

Conference Call Tuesday August 13, 2024 at 4:30 p.m. ET SAN DIEGO, Aug. 13, 2024 (GLOBE NEWSWIRE) — Beam Global, (Nasdaq: BEEM), (the “Company”), a provider of innovative and sustainable infrastructure solutions for the electrification of transportation and energy security, today announced its second quarter results for the period ended Q2 2024. Q2 2024 Financial Highlights:Increased revenue 2% to $14.8 million over Q1 2024 Record gross margin of 16%, an increase over Q1 2024 of 6 percentage points 31% of revenue derived from commercial customers Backlog of $11 million; record pipeline of over $183 million Net cash used of $0.1 million in operating activities for the six months ended Q2 2024 Debt free and $100 million line of credit available and unusedQ2 2024 and Recent Operational Highlights:Q2 purchase orders up 129% year-over-year...

DENVER, Aug. 13, 2024 (GLOBE NEWSWIRE) — Inspirato Incorporated (“Inspirato” or the “Company”) (NASDAQ: ISPO), the innovative luxury travel club, today announced its 2024 second quarter financial and operating results, the closing of its previously announced $10 million Investment Agreement with One Planet Group LLC (“One Planet Group”) and is in the process of implementing initiatives expected to reduce costs by approximately $25 million on an annualized basis. Except as otherwise stated, all financial results discussed below are presented in accordance with generally accepted accounting principles in the United States of America, or GAAP. As supplemental information, we have provided certain additional non-GAAP financial measures in this press release’s supplemental tables, and such supplemental tables include a reconciliation...

• AMPLIFY-7P Phase 1 preliminary disease-free (“DFS”) survival demonstrates strong correlation between T cell response and reduced risk of progression or death• AMPLIFY-7P Phase 1 data presented at ASCO demonstrated 100% of patients develop mKRAS-specific T-cell response with ~66% of responses including both CD4+ and CD8+ T cells• Long term follow up of the AMPLIFY-201 Phase 1 study will be terminated, and long term follow up of the AMPLIFY-7P Phase 1 study will be minimized to collect only overall survival to preserve resources with updated data to be shared at upcoming medical meetings• AMPLIFY-7P Phase 2 randomized clinical trial anticipated to complete 135-patient enrollment in the fourth quarter of 2024• $43 million raised in 2024 funds Elicio into the second quarter of 2025 BOSTON, Aug. 13, 2024 (GLOBE NEWSWIRE) — Elicio...

Second consecutive quarter with positive Adjusted EBITDA*, increasing year-to-date Adjusted EBITDA* to $0.5 million, representing a $3.0 million year-on-year improvement 2% quarter-over-quarter increase in revenue to $6.6 million Operating expenses reduced by 35% year-on-yearBOCA RATON, Fla., Aug. 13, 2024 (GLOBE NEWSWIRE) — SpringBig Holdings, Inc. (“Springbig” or the “Company”) (OTCQX: SBIG), a leading provider of SaaS-based marketing solutions, consumer mobile app experiences, and omnichannel loyalty programs, today announced its financial results for the second quarter ended June 30, 2024. “We continue to make good progress. Our newer offerings, such as ‘subscriptions by Springbig’ and ‘gift cards by Springbig’ are gaining traction as our clients increasingly recognize the value and benefits of our broader suite of offerings”...

– Sutro will present updated data from the ongoing Phase 1b study of luvelta in combination with bevacizumab in a poster presentation at ESMO 2024; expansion study is ongoing with data expected in the first half of 2025 – – REFRαME-O1 Part 2 (randomized portion) of the Phase 3 trial of luvelta for treatment of platinum-resistant ovarian cancer (PROC) is underway – – REFRαME-P1, a registration-enabling trial of luvelta for pediatric patients with CBFA2T3::GLIS2 (CBF/GLIS; RAM phenotype) AML, is expected to be initiated in the second half of 2024 – – A Phase 2 trial of luvelta for the treatment of NSCLC is expected to initiate in the second half of 2024, with initial data expected in the first half of 2025 – – As of June 30, 2024, Sutro had $426.0 million, composed of cash, cash equivalents...